Mizuho Medy Co Ltd
TSE:4595
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mizuho Medy Co Ltd
Cash & Cash Equivalents
Mizuho Medy Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mizuho Medy Co Ltd
TSE:4595
|
Cash & Cash Equivalents
¥10.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
188%
|
CAGR 10-Years
N/A
|
|
|
Terumo Corp
TSE:4543
|
Cash & Cash Equivalents
¥238B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Olympus Corp
TSE:7733
|
Cash & Cash Equivalents
¥169.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Sysmex Corp
TSE:6869
|
Cash & Cash Equivalents
¥75.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
JEOL Ltd
TSE:6951
|
Cash & Cash Equivalents
¥38B
|
CAGR 3-Years
2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
13%
|
|
|
Fukuda Denshi Co Ltd
TSE:6960
|
Cash & Cash Equivalents
¥63.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
Mizuho Medy Co Ltd
Glance View
Mizuho Medy Co., Ltd. engages in the research, development, manufacture and distribution of in-vitro diagnostic products. The company is headquartered in Tosu-Shi, Saga-Ken and currently employs 173 full-time employees. The company went IPO on 2015-12-17. The firm mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.
See Also
What is Mizuho Medy Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
10.8B
JPY
Based on the financial report for Dec 31, 2025, Mizuho Medy Co Ltd's Cash & Cash Equivalents amounts to 10.8B JPY.
What is Mizuho Medy Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
188%
Over the last year, the Cash & Cash Equivalents growth was -4%. The average annual Cash & Cash Equivalents growth rates for Mizuho Medy Co Ltd have been 8% over the past three years , 188% over the past five years .
